Alzheimer's Research UK is the UK's leading dementia research charity, dedicated to finding preventions, treatments, and ultimately a cure for Alzheimer's disease and other dementias[@alzheimers]. Founded in 1992 as the Alzheimer's Research Trust, the organization has invested over £100 million in cutting-edge research across the UK and internationally. As the largest charitable funder of dementia research in the UK, the charity brings together scientists, clinicians, and people affected by dementia to accelerate progress[@scheltens2023].
The organization funds research at universities and hospitals across the UK, focusing on understanding the diseases that cause dementia, developing new treatments, and improving diagnosis. Alzheimer's Research UK also plays a crucial role in raising awareness and challenging stigma around dementia. The charity's mission is to defeat dementia through world-class research, and its strategic vision encompasses all aspects of the research pipeline from basic science through to clinical translation.
Dementia represents one of the greatest global health challenges of the 21st century. According to recent estimates, over 55 million people worldwide are living with dementia, with nearly 10 million new cases diagnosed each year[@long2023]. In Europe alone, approximately 7 million people are affected, and the UK has one of the highest prevalence rates in the world with over 850,000 people living with dementia.
The economic impact is staggering, with dementia costing the UK economy over £34 billion annually—more than cancer, heart disease, and stroke combined. This includes direct healthcare costs, social care expenditure, and the enormous value of informal caregiving. Without effective treatments or prevention strategies, these costs are projected to rise dramatically as populations age.
Alzheimer's disease is the most common cause of dementia, accounting for approximately 60-70% of all cases. The disease is characterized by two key pathological hallmarks[@chen2023]:
Amyloid plaques: Accumulation of amyloid-beta (Aβ) peptides in the brain, forming extracellular plaques that disrupt neuronal function. The amyloid hypothesis has dominated Alzheimer's research for decades, though recent clinical trial results have complicated this narrative[@de2023].
Neurofibrillary tangles: Abnormal aggregation of tau protein inside neurons, leading to cell death. Tau pathology correlates more closely with cognitive decline than amyloid, making it an important therapeutic target.
Beyond these classical features, modern research has revealed the importance of[@ingel2023]:
The NIA-AA research framework provides a biological definition of Alzheimer's disease based on amyloid, tau, and neurodegeneration biomarkers, enabling more precise diagnosis and tracking of disease progression[@jack2023].
Alzheimer's Research UK funds research across multiple priority areas, reflecting the complexity of dementia and the need for multiple therapeutic approaches:
Understanding why Alzheimer's disease develops is fundamental to finding treatments. The charity funds research into[@balasa2023]:
Genetic Risk Factors: Genome-wide association studies have identified over 40 genetic loci associated with increased Alzheimer's risk. The APOE gene remains the strongest genetic determinant, with the ε4 allele increasing risk approximately 3-4 fold[@linden2023]. Other important genes include TREM2, which plays a critical role in microglial function[@yerbury2023], and variants in genes involved in immune function, lipid metabolism, and synaptic plasticity.
Molecular Mechanisms: Research into the fundamental biology of Alzheimer's disease, including:
Lifestyle and Environmental Factors: Studies examining modifiable risk factors including:
Early and accurate diagnosis is crucial for effective intervention. The charity supports research into[@van2023]:
Biomarker Development: Identification of biological markers that can detect Alzheimer's pathology before symptoms appear:
Neuroimaging Advances: Supporting the development and validation of:
Digital Biomarkers: Emerging technologies including:
The charity funds research across the therapeutic pipeline[@cummings2023]:
Disease-Modifying Therapies: Targeting the underlying biology of Alzheimer's:
Symptomatic Treatments: Improving cognitive function and managing behavioral symptoms:
Prevention Strategies: Reducing dementia risk through:
The Drug Discovery Alliance[@drug] is a pioneering initiative that brings together three leading UK universities to accelerate the development of new treatments:
University of Cambridge: The Cambridge Drug Discovery Unit focuses on:
University of Oxford: The Oxford Drug Discovery Institute specializes in:
UCL (University College London): The UCL Drug Discovery Institute emphasizes:
This unique partnership leverages the complementary strengths of each institution, creating a world-class drug discovery pipeline. The Alliance has established automated screening facilities, created a compound library of over 500,000 compounds, and generated numerous hit compounds for further development.
A strategic partnership focused on understanding disease mechanisms and developing novel therapeutic approaches. This collaboration brings together:
The partnership emphasizes translational research, moving discoveries from basic science through to clinical application. Key focus areas include synaptic dysfunction, neuroinflammation, and vascular contributions to dementia.
Alzheimer's Research UK funds research using induced pluripotent stem cells (iPSCs) to model Alzheimer's disease in human cells. This approach offers significant advantages:
The charity has established stem cell resources and supported the development of iPSC models from patients with genetic forms of Alzheimer's, including those with APP and PSEN1 mutations.
Through major investments in genomic research, the charity has contributed to:
These investments have helped identify novel genetic risk factors and provided insights into disease mechanisms that are informing drug discovery efforts.
Alzheimer's Research UK plays a crucial role in supporting clinical trials:
The charity has supported numerous landmark trials, including those for lecanemab and donanemab, and continues to advocate for a robust clinical trials ecosystem in the UK.
Research funded by Alzheimer's Research UK has contributed to major advances in our understanding and treatment of dementia:
Drug Development: Research funded by the charity has contributed to the development of disease-modifying therapies now reaching patients. UK scientists played key roles in the development of lecanemab and donanemab, the first amyloid-targeting antibodies to show clinical benefit in large trials.
Genetic Discoveries: UK researchers funded by the charity have identified numerous genetic risk factors for Alzheimer's, including rare variants in TREM2, SORL1, and other genes. These discoveries have revealed new biological pathways and therapeutic targets.
Biomarker Advances: Research has advanced blood-based biomarkers for Alzheimer's, moving towards simple diagnostic tests that could transform early detection. The charity supported validation studies that are now enabling clinical implementation of these tests.
Imaging Innovation: UK researchers have pioneered new imaging techniques including:
The charity provides comprehensive, expert-reviewed information through its online Information Hub, featuring:
The Research Network involves people with dementia and their caregivers in the research process:
The charity runs campaigns to increase understanding and reduce stigma:
"Fund the Future": A major campaign advocating for increased investment in dementia research, highlighting the economic case for research funding and the human cost of inaction.
Public Awareness Initiatives: Raising the profile of dementia as a medical condition requiring research investment, challenging misconceptions that dementia is a normal part of aging.
Join Dementia Research is a national registry that connects people with research opportunities[@alzheimersa]. The service:
Over 50,000 people have registered, enabling faster recruitment for research studies and clinical trials.
Alzheimer's Research UK advocates for policies that support dementia research and care:
Research Funding: Calling for increased government investment in dementia research, aiming for a level of funding proportional to the disease burden. The charity advocates for at least £100 million additional annual government investment in dementia research.
Early Diagnosis: Promoting earlier diagnosis of dementia through:
Access to Treatments: Ensuring new disease-modifying therapies reach patients:
The charity maintains active engagement with Parliament:
Working with international partners to:
Alzheimer's Research UK works with global partners:
Alzheimer's Association (US): Joint international initiatives including:
Dementia Research Institutes: UK-wide network of research centers bringing together:
European Alzheimer's Disease Consortium: Collaborative research across Europe:
The charity funds research at leading UK universities:
Working with pharmaceutical and biotech companies:
Collaborating with other organizations:
Alzheimer's Research UK is governed by:
The charity is committed to transparency:
Alzheimer's Research UK has outlined ambitious goals for the coming decade:
The charity is investing in:
The charity aims to maintain the UK's position as a world leader in dementia research: